**Background**
Major depressive disorder and anxiety are complex neurological conditions often associated with the dysregulation of monoamine neurotransmitters, including serotonin (5-HT), norepinephrine, and dopamine. The modulation of serotonin receptors and the inhibition of monoamine transporters are primary strategies in the development of antidepressant and anxiolytic therapies. Specifically, targeting the 5-HT receptor subtypes and organic cation transporters can help restore neurochemical balance in the brain. Given its ability to cross the blood-brain barrier and its multi-target profile, trimipramine has been extensively studied for its therapeutic potential. In this context, we will introduce a potent 5-HT receptor antagonist and transporter inhibitor – Trimipramine.
**Definition**
Trimipramine is a 5-HT receptor antagonist and a selective inhibitor of human noradrenaline (hNAT), serotonin (hSERT), and organic cation transporters (hOCT1, hOCT2), with hSERT IC50 values of 2.11 μM.
**In Vitro and In Vivo Studies**
According to the Trimipramine description, this compound exhibits distinct binding affinities for various serotonin receptors, with pKi values of 8.10, 6.39, and 4.66 for 5-HT2, 5-HT1C, and 5-HT1A, respectively. Trimipramine in vitro studies using HEK293 cells demonstrated that it acts as a moderate inhibitor of human NAT (IC50 = 4.99 μM) and SERT (IC50 = 2.11 μM), suggesting that these transporters are key targets for its antidepressant effects.
Regarding Trimipramine in vivo activity, chronic administration (5 mg/kg/day for 14 days) via subcutaneous osmotic minipumps in male Wistar rats (220-250 g) resulted in significant neurochemical changes. The treatment increased the concentration of regional 5-HT, particularly in the hippocampus and frontal cortex, and elevated the levels of monoamines and their metabolites, indicating an increased synthesis rate for dopamine (DA) and 5-HT. Furthermore, this chronic treatment led to an adaptive downregulation, decreasing the number of 5-HT2 receptors in the frontal cortex and DA D2 receptors in the striatum, effectively blocking the uptake of 5-HT and dopamine. In conclusion, Trimipramine is a multi-target agent with potent vascular activity and anxiolytic efficacy.
Keywords
Trimipramine, 521-78-8, 5-HT Receptor, Bacterial, Serotonin Receptor, 5-hydroxytryptamine Receptor, antidepressants, 5-HT, 5-hydroxytryptamine, serotonin, 5-HTlc receptors, 5-HTIA receptors, dopamine, DA, DA D2 receptor, 5-HT1C, 5-HT2, 5-HT1A, anxiolytic, neurological disease, noradrenaline, hNAT, hSERT, hDAT, human organic cation transporters, hOCT1, hOCT2, hOCT3
References
[1] Jenck F, et al. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol. 1993 Feb 9;231(2):223-9.
[2] Juorio AV, et al. The effects of chronic trimipramine treatment on biogenic amine metabolism and on dopamine D2, 5-HT2 and tryptamine binding sites in rat brain. Gen Pharmacol. 1990;21(5):759-62.
[3] Haenisch B, et al. Inhibitory potencies of trimipramine and its main metabolites at human monoamine and organic cation transporters. Psychopharmacology (Berl). 2011 Sep. 217(2):289-95.